The Valley Desk

NCT00661427 · Interventional trial

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Overall registry status Completed

Phase 2

Conditions Head and Neck, Squamous Cell Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov